Pediatrix Medical Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US58502B1061
USD
22.29
-1 (-4.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pediatrix Medical Group, Inc. stock-summary
stock-summary
Pediatrix Medical Group, Inc.
Pharmaceuticals & Biotechnology
MEDNAX, Inc is a provider of physician services, including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. The Company's national network consist of physicians, including over physicians providing neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. It also has affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. Its network also included other pediatric subspecialists, physicians providing pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat and pediatric ophthalmology services.
Company Coordinates stock-summary
Company Details
1301 Concord Ter , SUNRISE FL : 33323-2843
stock-summary
Tel: 1 954 38401751 954 3840175
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 72 Schemes (53.11%)

Foreign Institutions

Held by 107 Foreign Institutions (7.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Guy Sansone
Independent Chairman of the Board
Mr. Manuel Kadre
Lead Independent Director
Dr. Roger Medel
Director
Ms. Karey Barker
Independent Director
Dr. Waldemar Carlo
Independent Director
Mr. Paul Gabos
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
469 Million
(Quarterly Results - Jun 2025)
Net Profit:
39 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,476 Million (Small Cap)

stock-summary
P/E

8.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.33

stock-summary
Return on Equity

18.01%

stock-summary
Price to Book

1.77